FDA
-
-
-
-
-
-
-
Outlook Therapeutics posts Q3 loss, eyes U.S. LYTENAVA launch by end of 2026
-
-
-
-
-
-
-
Jefferies Upgrades Minerva Neurosciences (NERV) to Buy
-
-
-
-
-
-
-
FDA grants emergency use for Simparica TRIO to treat screwworm in dogs
-
-
-
-
-
-
-
Sintx Technologies regains Nasdaq stockholders' equity compliance
-
-
-
-
-
-
-
MiNK Therapeutics reports Q2 2026 results and Phase 2 trial data
-
-
-
-
-
-
-
Bluejay Diagnostics completes enrollment in IL-6 pivotal study
-
-
-
-
-
-
-
Zipalertinib combo meets Phase 3 trial goal in lung cancer study
-
328,604 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

